key: cord-0316187-k28g76f2
authors: Gupta, N.; Kaur, H.; Yadav, P.; Mukhopadhyay, L.; Sahay, R. R.; Kumar, A.; Nyayanit, D. A.; Shete, A. M.; Patil, S.; Majumdar, T. D.; Rana, S.; Gupta, S.; Narayan, J.; Vijay, N.; Barde, P.; Natrajan, G.; B, A. K.; Kumari, M. P.; Biswas, D.; Iravane, J.; Raut, S.; Dutta, S.; Devi, S.; Barua, P.; Gupta, P.; Borkakoty, B.; Kalita, D.; Dhingra, K.; Fomda, B.; Joshi, Y.; Goyal, K.; John, R.; Munivenkatappa, A.; Dhodapkar, R.; Pandit, P.; Dudhmal, M.; Kinariwala, D.; Khandelwal, N.; Tiwari, Y. K.; Khatri, P. K.; Gupta, A.; Khatri, H.; Malhotra, B.; Nagasundaram, M.; Dar, L.; Sheikh, N.; Ag,
title: Clinical characterization and Genomic analysis of COVID-19 breakthrough infections during second wave in different states of India
date: 2021-07-15
journal: nan
DOI: 10.1101/2021.07.13.21260273
sha: 093aaa70cd2280346b0059ccb73a0a21bcfb6e4b
doc_id: 316187
cord_uid: k28g76f2

During March to June 2021 India has experienced a deadly second wave of COVID19 with an increased number of post vaccination breakthrough infections reported across the country. To understand the possible reason of these breakthroughs we collected 677 clinical samples (throat swab/ nasal swabs) of individuals who had received two doses (n=592) and one dose (n=85) of vaccines (Covishield and Covaxin,) and tested positive for COVID19, from 17 states/Union Territories of country. These cases were telephonically interviewed and clinical data was analyzed. A total of 511 SARS-CoV-2 genomes were recovered with genome coverage of higher than 98% from both the cases. Analysis of both the cases determined that 86.69% (n=443) of them belonged to the Delta variant along with Alpha, Kappa, Delta AY.1 and Delta AY.2. The Delta variant clustered into 4 distinct sub-lineages. Sub-lineage I had mutations: ORF1ab, A1306S, P2046L, P2287S, V2930L, T3255I, T3446A, G5063S, P5401L, A6319V and N G215C; Sub lineage II : ORF1ab P309, A3209V, V3718A, G5063S, P5401L and ORF7a L116F; Sub lineage III : ORF1ab A3209V, V3718A, T3750I, G5063S, P5401L and Spike A222V; Sub-lineage IV ORF1ab P309L, D2980N, F3138S and spike K77T. This study indicated that majority of the clinical cases in the breakthrough were infected with the Delta variant and only 9.8% cases required hospitalization while fatality was observed in only 0.4% cases. This clearly suggests that the vaccination does provide reduction in hospital admission and mortality.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was reported from Wuhan in December 2019 and rapidly spread across the globe. The World Health Organization (WHO) declared it as a Public Health Emergency of International Concern on 11th March, 2020. Since then, the virus is continuously evolving and the first major mutation was seen in Spike-protein (D614G) which led to increased infectivity [1] . However, several new SARS-CoV-2 variants of concern (VOC) i.e., Alpha (B.1.1.7), Beta (B.1.35) and Gamma (B.1.1.28.1) have been detected from United Kingdom, South Africa and Brazil respectively during September to December 2020 and have also been reported from India [2] [3] [4] . Our earlier study of genomic surveillance from January-August 2020 showed absence of VOC/VUI and presence of G, GR and GH clade in the country with number of mutations [5] . The circulation of variants globally, enhanced the effect of COVID-19 pandemic with increased transmissibility, enhanced severity of illness, diminished protection relative to previous SARS-CoV-2 variant infection, lower response to vaccines and monoclonal antibodies [6] [7] [8] .

Since the worldwide alert of VOCs, the international travellers arriving at Indian airports from different countries from December 2020 till date were tracked and subjected to SARS-CoV-2 dose of vaccine as of 6 th July 2021 [12] .

Protection offered by vaccines is being questioned following the emergence of VOCs and reduced real world effectiveness of certain candidate vaccines against these variants. Israel reported breakthrough COVID-19 infections in individuals immunized with the Pfizer vaccine on 9 th April, 2021 [13] . India started observing a second upsurge in the number of COVID-19 cases from March 2021 onwards followed by a devastating second wave. Further in April, 2021 reduction in neutralization capacity of Covishield/AstraZeneca vaccinated sera against the B.1.1.7 variant as compared to the ancestral strain was observed during in-vitro studies [14, 15] . [16] . Further, post vaccination . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 15, 2021 [17] . Breakthrough infections in healthcare workers vaccinated with the BNT162b2 vaccine were reported from Italy in the month of May, 2021 during an outbreak of SARS-CoV-2 lineage B.1.1.7 [18] . In India, few studies reported breakthrough infections in small parts of the country like Kerala [19] and Delhi [20] . Taking cognizance of such reports, in April-May, 2021, a nationwide study was undertaken to understand the clinico-demographic profile of patients and SARS-CoV-2 strains responsible for post vaccination breakthrough COVID-19 infections across the country. To our understanding, this is the largest and first nation-wide study of post-vaccination breakthrough infections from India.

The is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 15, 2021. ; https://doi.org/10.1101/2021.07.13.21260273 doi: medRxiv preprint Delhi) during April-May, 2021. These clinical specimens were sequenced using next generation sequencing (NGS) to determine nucleotide variations in the SARS-CoV-2 genome from these strains.

Cases fulfilling the following inclusion criteria were enrolled under the study: i) cases who Therefore, it was not possible to track COVID-19 breakthrough infections in these states and they were not included in this study.

Though completely filled SRFs were requested along with the specimens, most of the forms received from laboratories were incomplete due to increased testing load during the second wave of COVID-19 in India. Therefore, telephonic interviews were conducted wherein each breakthrough case was called and interviewed individually during the period of 25th May to 14th

June, 2021. The telephonic interviews also helped in validating the information available in the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 15, 2021. pandemic in India. Out of these, 15 patients were not vaccinated for COVID-19, while 2 patients didn't give any vaccination history, and 120 patients could not be traced. Thus, a total of 137 patients were excluded and a total of 677 cases were included in the study.

Total RNA was extracted from 200-400 μ l of NS/OS swab samples using an automated RNA extraction system (Thermofisher, USA) using Magmax RNA extraction kit (Applied Biosystems, USA). Real time RTPCR was set using SARS-CoV-2 specific primers for the detection of E gene and RdRP gene as described earlier [21] . Illumina Covidseq protocol (Illumina Inc, USA) was followed for preparation of RNA libraries. Extracted RNA was annealed using random hexamers to prepare for cDNA synthesis. First strand cDNA was synthesized using reverse transcriptase. The synthesized cDNA was amplified in two separate PCR plates using two pools of primers (Pool 1 and Pool 2) covering entire genome of the SARS-CoV-2. Amplified cDNA was then tagmented and bead-based post tagmentation clean-up was performed. Tagmented amplicon were further amplified in this step using a PCR program as per manufactures instructions (Covidseq reference guide, Illumina). This PCR step adds pre-paired 10 base pair . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 15, 2021. ; https://doi.org/10.1101/2021.07.13.21260273 doi: medRxiv preprint Indexes (Set 1, 2, 3, 4 adapters), required for sequencing cluster generation. One Covidseq positive control (CPC) and one negative template control (NTC) were used for each 96-well plate. Libraries generated in batch of 96 samples per plate were pooled into one 1.7 ml tube.

Libraries of optimal size were purified by using magnetic bead based cleanup process method. The files were analyzed using the reference-based mapping method as implemented in CLC genomics workbench version 20.0 (CLC, QIAGEN, and Germany). The Wuhan Hu-1 isolate (Accession Number: NC_045512.2) was used as the reference sequence to retrieve the genomic sequence of the SARS-CoV-2. The retrieved sequences were aligned along with few representative sequences from GISAID database in CLC genomic Work bench v.20. A phylogenetic tree was generated using the MEGA software [22] for the aligned sequences. Gene wise amino acid mutations were also observed.

Detailed distribution of breakthrough cases (n=677) collected from 17 states/UT of the country used for NGS is provided in Table- Clinical data was analyzed for 677 breakthrough cases. The median age (and the IQR) of patients in the study was 44 (31-56), with the breakthrough cases after one dose was 53 (45-61) and after two doses was 41(30-55). A total of 441 (65.1%) of the breakthrough cases were males.

A total of 482 cases (71%) were symptomatic with one or more symptoms, while 29% had asymptomatic SARS-CoV-2 infection. Fever (69%) was the most consistent presentation followed by body ache including headache and nausea (56%), cough (45%), sore throat (37%), loss of smell and taste (22%), diarrhoea (6%), breathlessness (6%) and 1% had ocular irritation and redness. The clinical and demographic analysis of the 677 cases of breakthrough infections are is enumerated in Table 2 .

Co-morbidities were observed in the 154 out of 677 cases which included diabetes mellitus type-II, hypertension as well as chronic cardiac, renal and pulmonary diseases and obesity. The symptoms reported in patients with breakthrough infections are enumerated in Figure 1 . The comorbid cases were significantly pre-disposed to develop symptoms [cough, sore throat, fever, loss of smell and taste, diarrhoea, breathlessness, ocular symptoms and constitutional symptoms (body ache, headache, nausea)]; (OR=2.0042, 95% C.I.=1.2857 to 3.1244, z-statistic=3.069, p=0.0021). Also the co-morbid breakthrough cases were significantly more predisposed to hospitalization (OR=3.1779, 95% C.I.=1.8886 to 5.3471, z-statistic=4.355, p<0.0001).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 15, 2021. 

Globally, COVID-19 vaccines were accorded EUA and introduced quickly into the public health program to prevent SARS-CoV-2 infections and curtail disease transmission, thus saving lives and livelihood. However, the emergence of SARS-CoV-2 VOCs has raised a public health concern due to increased transmissibility and potential to evade humoral immune response. Apparently, it has also coincided with the introduction of global COVID-19 vaccination program which has created dilemma about the efficacy of vaccines under EUA.

Several studies have reported the reduction in the neutralization potential of the sera of individuals vaccinated with ChAdOx1 nCoV-19 (86×), mRNA-1273 (8.6×), BNT162b2 (6.5×) and BBIBP-CorV (1.6×) against Beta variant [23] . Beside this, the vaccine sera of BNT162b2 mRNA (7×) and one dose of ChAdOx1 nCoV-19 had also shown reduced neutralization against Delta variant [24] .

As per the WHO classification, the Delta variant has been designated as a variant of concern due to increased transmission and higher immune evasion, whereas other two sublineages of B. 1.617 namely B.1.617.1 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 15, 2021. ; https://doi.org/10.1101/2021.07.13.21260273 doi: medRxiv preprint dominance of Delta variant which accounted for >99% of all sequenced genomes in April 2021 [27] . A recent study on the secondary attack rates in UK households demonstrated a higher transmission of Delta compared to the Alpha variant [8] . A reduced neutralizing capability of currently used SARS-CoV-2 vaccines against Delta variants which is one of the causes for recent increase in the breakthrough cases with this strain.

Emergence of variant of concerns has led to upsurge in COVID-19 cases and second wave of pandemic in various countries including India. Incidentally, several countries have reported COVID-19 breakthrough infections even after completion of full vaccination schedule [16, 18, 28] . More than 10,000 breakthrough infections after completion of full course of vaccination has been reported in USA. Overall breakthrough infections were seen in smaller percentage of total vaccinated population [17] . A recent study has also reported mild symptomatic breakthrough infections from Kerala and Delhi, India [19, 20] .

The present study revealed the infection among breakthrough cases predominantly occurred through Delta variant indicating its high community transmission during this period followed by Alpha and Kappa variants. In our study, 67 cases (9.8%) required hospitalization and fatality was observed in only 3 cases (0.4%). This clearly suggests that vaccination reduces severity of disease, hospitalization and mortality. Therefore, enhancing the vaccination drive and immunizing the populations quickly would be the most important strategy to prevent further deadly waves of the COVID-19 and would reduce the burden on the health care system.

Two new SARS-CoV-2 variants Delta AY.1 and AY.2 were also identified in these study samples. Delta AY.1 and AY.2 is characterized by the presence of K417N mutation in the spike protein region. K417N, E484K, L452R, and E484Q are the mutations known to disrupt receptor . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 15, 2021. ; https://doi.org/10.1101/2021.07.13.21260273 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 15, 2021. ; https://doi.org/10.1101/2021.07.13.21260273 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 15, 2021. ; https://doi.org/10.1101/2021.07.13.21260273 doi: medRxiv preprint *p=0.0086 and odds ratio = 0.44 for the proportions with symptomatic among vaccinated with two doses and vaccinated with one dose. *p=0.0328 and Odds ratio = 0.49 for the proportions with individuals hospitalized with comorbidities and individuals hospitalized with non-comorbidities.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 15, 2021. ; https://doi.org/10.1101/2021.07.13.21260273 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 15, 2021. ; https://doi.org/10.1101/2021.07.13.21260273 doi: medRxiv preprint

The D614G Mutation in the SARS-CoV-2 Spike Protein Reduces S1 Shedding and Increases Infectivity

Isolation and Characterization of the New SARS-CoV-2 Variant in Travellers from the United Kingdom to India: VUI-202012/01 of the B.1.1.7 Lineage

Neutralization of B.1.1.28 P2 Variant with Sera of Natural SARS-CoV-2 Infection and Recipients of Inactivated COVID-19 Vaccine Covaxin

Imported SARS-CoV-2 V501Y.V2 Variant (B.1.351) Detected in Travelers from South Africa and Tanzania to India

Genomic Sequences from Different Regions of India

A Dynamic Nomenclature Proposal for SARS-CoV-2 Lineages to Assist Genomic Epidemiology

Sixteen Novel Lineages of SARS-CoV-2 in South Africa

Genomics and Epidemiology of a Novel SARS-CoV-2 Lineage in Manaus

Neutralization against B.1.351 and B.1.617.2 with Sera of COVID-19 Recovered Cases and Vaccinees of BBV152

Convergent Evolution of SARS-CoV-2 Spike Mutations, L452R, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Evidence for Increased Breakthrough Rates of SARS-CoV-2 Variants of Concern in BNT162b2-MRNA-Vaccinated Individuals

Efficacy of ChAdOx1 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 Variant of Concern 202012/01 (B.1.1.7): An Exploratory Analysis of a Randomised Controlled Trial

Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant by Convalescent and Vaccine Sera

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

CDCMMWR COVID-19 Vaccine Breakthrough Infections Reported to CDC -United States

Investigation of an Outbreak of Symptomatic SARS-CoV-2 VOC 202012/01-Lineage

Genomic Survey of SARS-CoV-2 Vaccine Breakthrough Infections in Healthcare Workers from Kerala

Breakthrough COVID19 Infections after Vaccinations in Healthcare and Other Workers in a Chronic Care Medical Facility

Development of in Vitro Transcribed RNA as Positive Control for Laboratory Diagnosis of SARS-CoV-2 in India

Molecular Evolutionary Genetics Analysis across Computing Platforms

New SARS-CoV-2 Variants -Clinical, Public Health, and Vaccine Implications

Resurgence of SARS-CoV-2 in India: Potential Role of the B.1.617.2 (Delta) Variant and Delayed Interventions

Maharashtra: Double Mutant Found in 61% Samples Tested

Karthik Gangavarapu, Laura D. Hughes, and the Center for Viral Systems Biology outbreak

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California

Vaccine-Escape and Fast-Growing Mutations in the United Kingdom, the United States